The immunological and genetic aspects in psoriasis
暂无分享,去创建一个
[1] Sally Attia,et al. Epidermal Differentiation Complex , 2010 .
[2] M. Madsen,et al. Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. , 2006, The Journal of investigative dermatology.
[3] A. Bowcock,et al. The genetics of psoriasis: a complex disorder of the skin and immune system. , 1998, Human molecular genetics.
[4] James T. Elder,et al. Multiple Loci within the Major Histocompatibility Complex Confer Risk of Psoriasis , 2009, PLoS genetics.
[5] W. Jochum,et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. , 1994, The Journal of investigative dermatology.
[6] Lisa C. Zaba,et al. Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.
[7] B. Thiers. Pathogenesis and clinical features of psoriasis , 2008 .
[8] Alkes L. Price,et al. New approaches to population stratification in genome-wide association studies , 2010, Nature Reviews Genetics.
[9] Matti Pirinen,et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity , 2012 .
[10] A. Kimball,et al. The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. , 2009, Journal of the American Academy of Dermatology.
[11] Scott F. Saccone,et al. A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci , 2008, PLoS genetics.
[12] E. Christophers,et al. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. , 1985, Journal of the American Academy of Dermatology.
[13] V. Álvarez,et al. New psoriasis susceptibility genes: momentum for skin-barrier disruption. , 2011, The Journal of investigative dermatology.
[14] L. Fouser,et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides , 2006, The Journal of experimental medicine.
[15] Christian Gieger,et al. Genome-wide association analysis identifies three psoriasis susceptibility loci , 2010, Nature Genetics.
[16] R. Trembath,et al. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. , 2002, American journal of human genetics.
[17] Liangdan Sun,et al. Identification of a missense variant in LNPEP that confers psoriasis risk. , 2014, The Journal of investigative dermatology.
[18] A. Magener,et al. Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1 , 2009, Journal of Medical Genetics.
[19] A. Gottlieb,et al. Differential Expression of Phosphorylated NF-κB/RelA in Normal and Psoriatic Epidermis and Downregulation of NF-κB in Response to Treatment with Etanercept , 2005 .
[20] F. Morel,et al. A role for T cell‐derived interleukin 22 in psoriatic skin inflammation , 2007, Clinical and experimental immunology.
[21] L. Herrinton,et al. The association of psoriasis with autoimmune diseases. , 2012, Journal of the American Academy of Dermatology.
[22] James G. Krueger,et al. Pathogenesis and therapy of psoriasis , 2007, Nature.
[23] S. Kaesler,et al. CXCL16 and CXCR6 are upregulated in psoriasis and mediate cutaneous recruitment of human CD8+ T cells. , 2012, The Journal of investigative dermatology.
[24] N. J. Eungdamrong,et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. , 2009, The Journal of investigative dermatology.
[25] A. Bowcock,et al. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. , 2004, Trends in immunology.
[26] K. Asadullah,et al. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype , 2000, Archives of Dermatological Research.
[27] Pui-Yan Kwok,et al. Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways , 2008, Nature Genetics.
[28] B. Kirby,et al. TNFα Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis , 2012, BioDrugs.
[29] D. Wallach,et al. Elevated tumour necrosis factor‐alpha (TNF‐α) biological activity in psoriatic skin lesions , 1994, Clinical and experimental immunology.
[30] John BowesRobert. Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis , 2010 .
[31] Christian Gieger,et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis , 2010, Nature Genetics.
[32] Wei Huang,et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21 , 2009, Nature Genetics.
[33] W. Mueller,et al. Cyclosporin A for psoriasis. , 1979, The New England journal of medicine.
[34] J. Renauld,et al. IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice , 2011, The Journal of Immunology.
[35] A. Bowcock,et al. Psoriasis: genetic associations and immune system changes , 2007, Genes and Immunity.
[36] V. Kuchroo,et al. Interleukin-17 and type 17 helper T cells. , 2009, The New England journal of medicine.
[37] H. Spits,et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells , 2009, Nature Immunology.
[38] C. Johansen,et al. Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. , 2007, The Journal of investigative dermatology.
[39] F. Nestle,et al. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. , 2009, The Journal of investigative dermatology.
[40] A. Bowcock,et al. PSORS2 is due to mutations in CARD14. , 2012, American Journal of Human Genetics.
[41] Richard C Trembath,et al. Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. , 2008, Human molecular genetics.
[42] Lisa C. Zaba,et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. , 2008, The Journal of investigative dermatology.
[43] G. T. te Meerman,et al. Evaluation of the IRF-2 gene as a candidate for PSORS3. , 2004, The Journal of investigative dermatology.
[44] Raquel Soares,et al. Angiogenesis and chronic inflammation: cause or consequence? , 2007, Angiogenesis.
[45] I. Marenholz,et al. Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21. , 1996, The Journal of investigative dermatology.
[46] J. Catanese,et al. The autoimmune disease-associated IL12B and IL23R polymorphisms in multiple sclerosis. , 2007, Human immunology.
[47] W. Boehncke,et al. Animal models of psoriasis. , 2007, Clinics in dermatology.
[48] Liangdan Sun,et al. Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. , 2007, The Journal of investigative dermatology.
[49] T. Wienker,et al. Genomewide scan in german families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13. , 2000, American journal of human genetics.
[50] A. Reis,et al. Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confirms a role in susceptibility to psoriasis vulgaris. , 2005, The Journal of investigative dermatology.
[51] K. Scharffetter-Kochanek,et al. Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis. , 2009, The Journal of investigative dermatology.
[52] James T. Elder,et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. , 1997, Human molecular genetics.
[53] Stefan Jenisch,et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. , 2006, American journal of human genetics.
[54] A. Bowcock,et al. Getting under the skin: the immunogenetics of psoriasis , 2005, Nature Reviews Immunology.
[55] B. Kamińska,et al. Targeting signaling pathways with small molecules to treat autoimmune disorders , 2008, Expert review of clinical immunology.
[56] Christian Gieger,et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2 , 2010, Nature Genetics.
[57] Jinhua Xu,et al. Transcriptional regulatory network for psoriasis , 2013, The Journal of dermatology.
[58] F. Nestle,et al. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. , 1994, The Journal of clinical investigation.
[59] Wei Li,et al. Follow-up analysis of PSORS9 in 151 Chinese families confirmed the linkage to 4q31-32 and refined the evidence to the families of early-onset psoriasis. , 2007, The Journal of investigative dermatology.
[60] J. Riley,et al. Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden , 1999, European Journal of Human Genetics.
[61] Jun Yan,et al. New insights of T cells in the pathogenesis of psoriasis , 2012, Cellular and Molecular Immunology.
[62] M. Yamamura,et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. , 1993, The Journal of investigative dermatology.
[63] A. Gottlieb,et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. , 2005, The Journal of investigative dermatology.
[64] F. Nestle,et al. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. , 2004, The Journal of clinical investigation.
[65] Mark Lebwohl,et al. Psoriasis , 1906, The Lancet.
[66] N. Rose. Autoimmune diseases. , 1981, Scientific American.
[67] B. Kirby,et al. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. , 2005, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[68] Xuejun Zhang,et al. Association of HLA class I alleles with psoriasis vulgaris in southeastern Chinese Hans. , 2003, Journal of dermatological science.
[69] K. Nakajima. Critical role of the interleukin‐23//T‐helper 17 cell axis in the pathogenesis of psoriasis , 2012, The Journal of dermatology.
[70] J. Todd,et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus , 2009, Genes and Immunity.
[71] P. Valdez,et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.
[72] O. Boyman,et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production , 2005, The Journal of experimental medicine.
[73] O. Lunov,et al. Targeting NF-κB with a Natural Triterpenoid Alleviates Skin Inflammation in a Mouse Model of Psoriasis1 , 2009, The Journal of Immunology.
[74] L. Samuelsson,et al. Association analysis of cystatin A and zinc finger protein 148, two genes located at the psoriasis susceptibility locus PSORS5. , 2004, The Journal of investigative dermatology.
[75] J. Carucci,et al. Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production , 2009, Proceedings of the National Academy of Sciences.
[76] E. Fisher,et al. Evidence that a locus for familial psoriasis maps to chromosome 4q , 1996, Nature Genetics.
[77] C. Albanesi,et al. Keratinocytes in inflammatory skin diseases. , 2005, Current drug targets. Inflammation and allergy.
[78] R. Clark,et al. Misbehaving macrophages in the pathogenesis of psoriasis. , 2006, The Journal of clinical investigation.
[79] Steven J. Schrodi,et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. , 2007, American journal of human genetics.
[80] Gang Wang,et al. IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms. , 2011, The Journal of investigative dermatology.
[81] H. Young,et al. Impaired Langerhans cell migration in psoriasis , 2006, The Journal of experimental medicine.
[82] James T. Elder. PSORS1: linking genetics and immunology. , 2006, The Journal of investigative dermatology.
[83] R. Trembath,et al. Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci , 2001, Journal of medical genetics.
[84] A. Gottlieb,et al. NF-κB: an essential transcription factor in psoriasis. , 2013, Journal of dermatological science.
[85] Christian Gieger,et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. , 2012, American journal of human genetics.
[86] J. Arthur,et al. Signaling downstream of p38 in psoriasis. , 2006, The Journal of investigative dermatology.
[87] Ying Wang,et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus , 2009, Nature Genetics.
[88] N. Van Rooijen,et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. , 2006, The Journal of clinical investigation.
[89] B. Diamond,et al. Autoimmune diseases , 2000, Bone Marrow Transplantation.
[90] Matti Pirinen,et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1 , 2010, Nature Genetics.
[91] Renhua Wu,et al. A large-scale screen for coding variants predisposing to psoriasis , 2013, Nature Genetics.
[92] James T. Elder,et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population , 2010, Nature Genetics.
[93] Judy H. Cho,et al. A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.
[94] Gonçalo Abecasis,et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis , 2009, Nature Genetics.
[95] J. Gudjonsson,et al. Immunopathogenic mechanisms in psoriasis , 2004, Clinical and experimental immunology.
[96] Liangdan Sun,et al. Association analyses identifying two common susceptibility loci shared by psoriasis and systemic lupus erythematosus in the Chinese Han population , 2013, Journal of Medical Genetics.
[97] M. Amagai,et al. Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin , 1993, Nature.
[98] Andrew Blauvelt,et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. , 2009, The Journal of investigative dermatology.
[99] R. B. Kjellerup,et al. STAT1 expression and activation is increased in lesional psoriatic skin , 2013, The British journal of dermatology.
[100] V. Kuchroo,et al. TH-17 cells in the circle of immunity and autoimmunity , 2007, Nature Immunology.
[101] A. Gaspari. Innate and adaptive immunity and the pathophysiology of psoriasis. , 2006, Journal of the American Academy of Dermatology.
[102] J. Krueger. The immunologic basis for the treatment of psoriasis with new biologic agents. , 2002, Journal of the American Academy of Dermatology.
[103] Frank O. Nestle,et al. Mechanisms of Disease: Psoriasis. , 2009 .
[104] M. Dhodapkar,et al. Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris , 2004, The Journal of experimental medicine.
[105] F. Nestle,et al. Harnessing dendritic cells in inflammatory skin diseases , 2011, Seminars in immunology.
[106] P. Helliwell,et al. The prevalence of psoriatic arthritis in people with psoriasis. , 2009, Arthritis and rheumatism.
[107] Francis S Collins,et al. A HapMap harvest of insights into the genetics of common disease. , 2008, The Journal of clinical investigation.
[108] Robert M. Plenge,et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis , 2011, Nature Genetics.
[109] A. Menssen,et al. Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. , 2001, The Journal of investigative dermatology.